Loomis, Sayles & Company
RVNC

Loomis, Sayles & Company’s Revance Therapeutics, Inc. RVNC Stock Holding History

Loomis, Sayles & Company’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-358,393
Closed -$12.2M – 1152
2015
Q4 		$12.2M Buy
+358,393
New +$12.4M 0.03% 390

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Loomis, Sayles & Company's RVNC Position: Q1 2016 in Review

Loomis, Sayles & Company sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2016, closing a stake of 358,393 shares — an estimated $12.2M sold.

Loomis, Sayles & Company first reported a position in RVNC in Q4 2015 and held it in 1 quarter. The position peaked at $12.2M in Q4 2015. 86 funds tracked by Wall St. Rank hold RVNC as of Q1 2016.

  • Loomis, Sayles & Company reported no remaining Revance Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Loomis, Sayles & Company sold 358,393 Revance Therapeutics, Inc. shares in Q1 2016, an estimated $12.2M.
  • Loomis, Sayles & Company first reported a position in Revance Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Loomis, Sayles & Company's Revance Therapeutics, Inc. position peaked at $12.2M in Q4 2015.
  • 86 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2016.

Based on Loomis, Sayles & Company's 13F filing for Q1 2016, filed 13 May 2016.